Drug Trial Radar · NCT07929181
Efficacy and Safety of Polisorb® MP in the Complex Therapy of Patients With Atopic Dermatitis
Last checked: Nov 20, 2026Latest source record: Nov 10, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
161
Actual
Start
Apr 10, 2024
Primary completion
Nov 28, 2024
Study completion Nov 28, 2024
Sponsor
- Lead sponsor
- Polisorb Joint Stock CompanyIndustry
- Sponsor type
- Industry
- First posted
- Nov 10, 2026
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 65 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This multicenter, open-label, randomized Phase III clinical trial evaluated the efficacy and safety of adding Polisorb® MP, an oral colloidal silicon dioxide adsorbent, to basic therapy in adults with mild to moderate atopic dermatitis. The study included 161 patients in the efficacy analysis. Participants were randomly assigned to receive either basic therapy alone (81 patients) or basic therapy in combination with Polisorb® MP (80 patients). Basic therapy included skin care with emollients and pharmacological treatment, including cetirizine and topical pimecrolimus. The treatment period lasted 14 days, followed by an observation period. The primary endpoint was the change in the SCORAD index from baseline to Day 14. Itch intensity, dermatology-related quality of life, EASI and IGA scores were also assessed. Both groups showed improvement in disease severity during treatment. The mean SCORAD score decreased by 21.5 points in patients receiving Polisorb® MP in addition to basic therapy, compared with 17.7 points in patients receiving basic therapy alone. The difference between the groups was statistically significant (p = 0.0028), favoring the addition of Polisorb® MP. Improvements in itch intensity and IGA scores also favored combination therapy, while differences between groups in EASI changes and changes in dermatology-related quality of life were not statistically significant. A total of 34 adverse events were reported in 26 patients. No serious adverse events or deaths were reported. Gastrointestinal events, particularly constipation, were more frequent in the Polisorb® MP group. Other reported events included difficulty with defecation, abdominal discomfort, bloating, dry mouth and nausea. No new or unexpected safety concerns specific to Polisorb® MP were identified during the study. The findings indicate that adding Polisorb® MP to basic therapy was associated with a greater reduction in SCORAD scores over 14 days than basic therapy alone. The results should be interpreted in the context of the open-label design and the short treatment period.
Conditions
- Atopic Dermatitis
Interventions
Colloidal Silicon DioxideDrug
Polisorb® MP, an oral colloidal silicon dioxide adsorbent, was administered in addition to basic therapy for atopic dermatitis during the 14-day treatment period. The study evaluated the efficacy and safety of this combination compared with basic therapy alone.
Basic Therapy for Atopic DermatitisDrug
Basic therapy for atopic dermatitis consisted of emollient skin care and pharmacological treatment, including cetirizine and topical pimecrolimus. It was administered for 14 days in accordance with the study protocol.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Change in Scoring Atopic Dermatitis (SCORAD) Index from Baseline to Day 14Time frame: Baseline to Day 14
Locations
7 sites in 1 country. Site status is shown where the registry gives one.
Chelyabinsk Regional Clinical Skin and Venereological Dispensary
Chelyabinsk, Russia
Clinical Skin and Venereological Dispensary
Krasnodar, Russia
Ryazan Regional Clinical Skin and Venereological Dispensary
Ryazan, Russia
Saint Petersburg State Medical Institution 'Skin and venereological dispensary No. 10'
Saint Petersburg, Russia
Reavita Med SPB LLC
Saint Petersburg, Russia
Skin and venereological dispensary No. 8
Saint Petersburg, Russia
City polyclinic No. 4
Saint Petersburg, Russia
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.